Alzheimer's disease personalized medicine

Abstract

ALCAM/CD166 has recently been discovered as a novel therapeutic target of Alzheimer's Disease and providing a personalized therapy thereof disclosed herein, wherein the personalized therapy in an embodiment of the invention, may include recombinant human fusion protein ILT3Fc or functional fragment thereof when the individual patient does not test positive (i.e., is a non-carrier) for the protective rs2030515 (G) SNP. The present disclosure is further directed to achieving successful ALCAM/CD166 target modulation by administration of a sufficient, and brain-penetrating intravenous dose of ILT3Fc, or alternatively or additionally, by direct CNS administration of a significantly reduced dose that achieves both CNS and peripheral systemic exposure; the disclosure is further directed to in-vivo circulating biomarkers of ALCAM/CD166 for application in neurodegenerative disease and related disorders.

Dependencies are inferred from the claim text.